Phase 2 N=23 Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 4.3; 14.5 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=63 Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Transplant-related Mortality — 8 participants
Phase 2 N=10 Memantine Treatment of Compulsive Buying
Compulsive Buying
Primary: Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) — 22 units on a scale
Phase 2 N=30 Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Melanoma
Primary: Cumulative Participants Response to Palonosetron — 85; 139; 44; 72 episodes of nausea/vomiting
Phase 2 N=25 Double-Blind Naltrexone in Kleptomania
Kleptomania
Primary: Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS) — 3.83; 11.46 units on a scale
Phase 2 N=87 Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 0.5; 3.6 percentage of ejection fraction — p=<0.05
Phase 2 N=155 Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes
Primary: Mean Change in HbA1c (Per Protocol) — -0.96; -1.04; -0.82 percent change
Phase 2 N=62 Prasugrel Versus Placebo in Adult Sickle Cell Disease
Sickle Cell Anemia
Primary: Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention During the Treatment Duration — 0; 0 percentage of participants
Phase 2 N=184 A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Qualitative Amyloid Image Assessment — 34; 23; 11; 11 participants — p=0.0002
Phase 2 N=32 Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
Leukemia
Primary: Number of Participants (With Increase) Immune Response to GM-CSF With a Pneumococcal Vaccine — 0; 0; 1; 1 participants
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=102 Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Total Severity Score (TSS) of Target Lesion at Baseline and Week 4 — 7.62; 7.49; 4.7; 4.6 score on a scale
Phase 2 N=63 S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Overall Survival at 6 Months — 36 percentage of participants
Phase 2 N=14 Treating Intention In Aphasia: Neuroplastic Substrates
Aphasia · Cerebrovascular Accident
Primary: Lateralization of Frontal Lobe (and Posterior Perisylvian) Activity During Word Production — -0.2802; -0.1832 laterality index — p=<.05
Phase 2 N=55 Oral Immunotherapy for Childhood Egg Allergy
Hypersensitivity · Immediate Hypersensitivity · Food Hypersensitivity
Primary: Percent of Participants Who Successfully Consumed 10,000 mg of Egg White Solid Followed by Open Feeding of Egg — 27.5; 0 percentage of participants — p=0.025